Nimotuzumab (Theraloc)
General information
Class/mechanism from the NCI Drug Dictionary: A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
Diseases for which it is used
History of changes in NMPA indication
- 2008-01-07: Initial approval in combination with RT for a treatment of nasopharyngeal carcinoma.
Also known as
- Code name: hR3
- Brand name: Theraloc